Department of Neuroscience,Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona,Verona,Italy.
Epidemiol Psychiatr Sci. 2018 Jun;27(3):227-229. doi: 10.1017/S2045796018000082. Epub 2018 Mar 12.
A substantial proportion of people with mental health conditions do not adhere to prescribed pharmacological treatments. Poor adherence is probably one of the most critical elements contributing to relapse in people with schizophrenia and other severe mental disorders. In order to tackle this global issue, in November 2017 the Food and Drug Administration approved a tablet formulation of the atypical antipsychotic aripiprazole embedded with a novel digital adherence-assessment device. In this commentary, we critically appraised the potential beneficial and harmful consequences of this new digital formulation of aripiprazole, and we highlighted expected implications for clinical practice.
相当一部分患有精神健康问题的人不遵守规定的药物治疗方案。治疗依从性差可能是导致精神分裂症和其他严重精神障碍患者病情复发的最重要因素之一。为了解决这个全球性问题，食品和药物管理局于 2017 年 11 月批准了一种将新型数字药物依从性评估装置嵌入其中的非典型抗精神病药阿立哌唑的片剂制剂。在这篇评论中，我们批判性地评估了这种新型阿立哌唑数字配方的潜在有益和有害后果，并强调了对临床实践的预期影响。
